semaglutide linked to cancer Disproportionality analysis of semaglutide-associated bile-duct cancer: A vigibase study | Indian Journal of Gastroenterology Ozempic and similar weight-loss drugs

Doz planlamas mutlaka doktor tarafndan yaplmaldr

Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss

Contact your healthcare provider immediately if thirst is accompanied by signs of severe dehydration, persistent vomiting or diarrhea lasting more than 24 hours, inability to keep fluids down, blood glucose consistently above 250 mg/dL, or symptoms of diabetic ketoacidosis

Stopping them may cause you to regain the weight you lost

Demi has always been thin and definitely does not look old - also she is in her 60s

Additional triggers for EDKA include pregnancy, pancreatitis, glycogen storage disorders, surgery, infection, cocaine toxicity, cirrhosis, and insulin pump use.[4][5] T1D bariatric surgery patients experience DKA in over 20% of postoperative cases and may be especially prone to EDKA.[6] The newer oral antidiabetic SGLT2 inhibitors, canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin, can also directly result in EDKA.[2][3][7][8][9][10] EDKA may be more common in patients with diabetes on SGLT2 inhibitors with lower body mass index and decreased glycogen stores.[1] Episodes can be triggered by surgery infection, trauma, a major illness, reduced food intake, persistent vomiting, gastroparesis, dehydration, and reduced insulin dosage.[11] Epidemiology Approximately 2.6% to 3.2% of DKA admissions are euglycemic.[7][12] DKA-associated with SGLT2 inhibitors has rates ranging from 0.16 to 0.76 events per 1000 patient-years in patients with type 2 diabetes